Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Harrow Inc HROW

Healthcare Drug Manufacturers - Specialty & Generic
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Health Shareholder Notice

Newsfile March 13, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW

PR Newswire March 13, 2023

Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO(TM) (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%

Business Wire March 13, 2023

HARROW HEALTH SHAREHOLDER ACTION REMINDER : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

PR Newswire March 11, 2023

Harrow Health Shareholder Action Reminder

Newsfile March 10, 2023

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

PR Newswire March 10, 2023

Harrow Health Investor Alert

Newsfile March 8, 2023

Harrow Health Shareholder Action Reminder

Newsfile March 6, 2023

Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

Business Wire March 6, 2023

HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

PR Newswire March 4, 2023

ROSEN, A Top Ranked Law Firm, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

Newsfile March 3, 2023

Harrow Health Shareholder Action Reminder

Newsfile March 2, 2023

ROSEN, LEADING INVESTOR COUNSEL, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

PR Newswire March 2, 2023

Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023

Business Wire March 2, 2023

Harrow Health Investor Alert

Newsfile March 1, 2023

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile March 1, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW

Newsfile February 27, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

Business Wire February 27, 2023

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

PR Newswire February 25, 2023

HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

PR Newswire February 25, 2023

Podcasts